A DNA-Based Diagnostic Company Rakes in £1.8M to Combat Antimicrobial Resistance

A new molecular diagnostics company, LIG Biowise, has just closed a £1.8M Series A fundraising round in its effort to combat antimicrobial resistance.

Based in Manchester, LIG Biowise, is working on a DNA-based diagnostic to catch antibiotic resistant infections early. The company has now closed a Series A of £1.8M (€2.0M), led by Hong Kong-based Phoenix Bridge, to fund the development of a ultra-rapid point-of-care molecular diagnostic for infectious respiratory diseases. The technology relies on combining DNA extraction, amplification and detection in a single step to catch infections quickly, accurately and for a lower cost.

Diagnostics are becoming big business in the face of the antimicrobial resistance crisis, as a result of which as many as 10 million people may be killed by 2050. Fortunately, technology in the field is really taking off: Another British biotech, Oxford Nanopore, made headlines last week when it published that its pocket DNA sequencer designed for diagnostic purposes had sequenced the human genome. Meanwhile, liquid biopsies are already well-established in cancer diagnosis.


Image via Kateryna Kon

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.